医学
肿瘤科
肺癌
微小残留病
内科学
阶段(地层学)
辅助治疗
循环肿瘤DNA
佐剂
癌症
生物
古生物学
白血病
作者
Shihua Dou,Hongsheng Xie,Lin Yang
标识
DOI:10.3779/j.issn.1009-3419.2021.102.44
摘要
Lung cancer is the most common malignant tumor in the world, among which non-small cell lung cancer (NSCLC) accounts for about 85% of the total number of lung cancers. The 5-year overall survial (OS) of radical surgery NSCLC patients ranged from 92% in stage Ia1 to 26% in stage IIIb, and the continuously decreasing survival time made it a strong clinical need for precise adjuvant therapy to eradicate molecular residual disease (MRD). At present, circulating tumor DNA (ctDNA) as a molecular indicator of MRD has gradually moved from the laboratory to the clinic. The latest consensus proposes that ctDNA with abundance ≥0.02% can be stably detected in the peripheral blood of perioperative NSCLC patients, which is based on the possibility of ctDNA as an MRD indicator. MRD detection technology supports the possibility of monitoring after radical treatment of NSCLC, and ctDNA can predict the recurrence of the disease earlier than the imaging monitoring after treatment of NSCLC, providing valuable time for timely adjustment of adjuvant therapy. In the studies on early postoperative adjuvant therapy of NSCLC, different guidelines differ on whether appropriate adjuvant therapy should be carried out, while MRD can be used as a more accurate predictor to guide postoperative adjuvant therapy, so that patients can benefit from the disease treatment. .【中文题目:基于ctDNA的MRD检测 在早期非小细胞肺癌根治术后的应用价值】 【中文摘要:肺癌是世界上最常见的恶性肿瘤,其中非小细胞肺癌(non-small cell lung cancer, NSCLC)约占肺癌总数的85%。接受手术的NSCLC患者的5年总生存期(overall survival, OS)从Ia1期的92%到IIIb期的26%,持续下降的生存期使其临床上有强烈的精准辅助治疗需求,以根除分子残留病灶(molecular residual disease, MRD)。目前循环肿瘤DNA(circulating tumor DNA, ctDNA)作为提示MRD的分子指标逐渐从实验室走向临床。最新共识提出在围手术期NSCLC患者外周血中可稳定检测出丰度≥0.02%的ctDNA,是基于ctDNA作为MRD指标的可能。MRD检测技术支持了NSCLC根治术后进行监测的可能性,而且ctDNA能比NSCLC治疗后的影像监测更早地预示着疾病的复发,为精准辅助治疗方案的制定提供了宝贵依据。在早期NSCLC术后辅助治疗研究中,不同指南对是否应该进行适合的辅助治疗存在分歧,而MRD可以作为一个更精准的预测指标,对术后辅助治疗进行指导,使患者能在疾病治疗中获益。 】 【中文关键词:肺肿瘤;ctDNA;MRD检测;辅助治疗;根治术】.
科研通智能强力驱动
Strongly Powered by AbleSci AI